ARDS Clinical Network Prospective, Randomized, Blinded, Placebo-controlled, Multi-center Trial of Omega-3 Fatty Acid, Gamma-Linolenic Acid, and Anti-Oxidant Supplementation in the Management of Acute Lung Injury or Acute Respiratory Distress Syndrome ARDS (OMEGA)

Objectives

This study was a prospective randomized controlled study of an omega 3 and antioxidant supplement added to usual feeding. Patients were followed to the earlier of 60 days or hospital discharge; vital status was ascertained at 180 days. The primary efficacy variable was ventilator-free days to study day 28. This study was stopped for futility after 272 patients. The OMEGA study was conducted on a subset of EDEN patients as a part of a factorial design.

Interested parties should review the Proprietary Study application process before they begin. Requests for Proprietary Studies must be approved by the Parent Study before they can be processed by BioLINCC. Contact information for the Parent Study is provided at the top of this webpage. Upon Parent Study approval, click the Request button to start a request through BioLINCC.